AGEN - יחס חוב להיוון בספרים Agenus, Inc.

Agenus (AGEN) generates revenue by developing immunotherapies for oncology centers, deriving profit through royalties and contracts with major corporations. The company's operations are based on bioethical principles and the eco-friendly processing of laboratory waste. The share price history, which currently stands at 0.00, reflects a decline driven by liquidity issues, debt, and FDA rejections of new product approvals.

For Agenus (AGEN), burdened by colossal oncology research costs and a liquidity deficit, this metric becomes a critical indicator of financial stability. By analyzing the company's debt relative to its book capitalization, an investor can see the proportion of borrowed funds to equity, which allows for an assessment of bankruptcy risk given the current burn rate of reserves and determines the business's need for emergency strategic financing.